Analysis | Metabolite Name | Measured Value | Units | Gender | Glycemic status | Neuropathy |
---|---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 11609 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 11664 | Peak area normalized | female | normoglycemic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 12379 | Peak area normalized | male | diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 12547 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 12661 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 13176 | Peak area normalized | female | normoglycemic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 13634 | Peak area normalized | male | pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 13890 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 16694 | Peak area normalized | male | pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 17421 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 18145 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 27307 | Peak area normalized | male | diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 28889 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 335392 | Peak area normalized | female | diabetic | no neuropathy |